Emerging roles of long non-coding RNA in cancer

Anna Sanchez Calle1 | Yumi Kawamura1,2 | Yusuke Yamamoto1 | Fumitaka Takeshita3 | Takahiro Ochiya1,4

1Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan
2Ph.D. Program in Human Biology, School of Integrative and Global Majors, University of Tsukuba, Tsukuba, Japan
3Department of Functional Analysis, FIOC, National Cancer Center Research Institute, Tokyo, Japan
4Institute of Medical Science, Tokyo Medical University, Tokyo, Japan

Correspondence
Takahiro Ochiya, Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan.
Email: tochiya@ncc.go.jp

Funding information
Japan Agency for Medical Research and Development (AMED; P-CREATE; 17cm0106217h0002); The Uehara Memorial Foundation research grant; The Naito Foundation research grant.

Since comprehensive analysis of the mammalian genome revealed that the majority of genomic products are transcribed in long non-coding RNA (lncRNA), increasing attention has been paid to these transcripts. The applied next-generation sequencing technologies have provided accumulating evidence of dysregulated lncRNA in cancer. The implication of this finding can be seen in many forms and at multiple levels. With impacts ranging from integrating chromatin remodeling complexes to regulating transcription and post-transcriptional processes, aberrant expression of lncRNA may have repercussions in cell proliferation, tumor progression or metastasis. lncRNA may act as enhancers, scaffolds or decoys by physically interacting with other RNA species or proteins, resulting in a direct impact on cell signaling cascades. Even though their functional classification is well-established in the context of cancer, clearer characterization in terms of their phenotypic outputs is needed to optimize and identify suitable candidates that enable the development of new therapeutic strategies and the design of novel diagnostic approaches. The present article aims to outline different cancer-associated lncRNA according to their contribution to tumor suppression or tumor promotion based on their most current functional annotations.

KEYWORDS
epithelial-to-mesenchymal transition, long non-coding RNA, tumor drivers, tumor plasticity, tumor suppressors

1 | INTRODUCTION

For several decades, non-protein-coding DNA was referred to as junk DNA, a term that has become obsolete. The large-scale genomic projects FANTOM and ENCODE revolutionized the study of the human genome and elucidated that, in fact, 80% of the genome harbors biochemical marks of active transcription and that solely 2% of the genome is restricted to protein coding.1,2 Thereby, the FANTOM and ENCODE platforms highlighted the pervasive way in which the genome is transcribed. Full-length cDNA sequencing profiles revealed new transcripts and new coding genes. Further optimization facilitated the detection of low-abundance transcripts that corresponded to antisense RNA and long non-coding RNA (lncRNA).3 With the observation of a gradually increased prevalence of non-coding DNA regions in superior organisms, together with recent genome-wide annotations in which 58,648 lncRNA account for 68% of the human transcriptome, the lncRNA class has gained more attention.4

Long non-coding RNA, which are defined as transcripts of more than 200 nucleotides that generally do not code for proteins, have been associated with diverse functions. Their biological contributions have been seen in the form of: (i) regulators of transcription in cis or trans; (ii) modulators of mRNA processing, post-transcriptional control and protein activity; and (iii) organization of nuclear domains.5,6

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Despite the elucidation of potential mechanistic roles, the biological relevance of the vast majority of lncRNA remains uncertain. In fact, their intricacy relies not only on their functional switch but also in their ability to be tissue/cell-specific. Furthermore, lncRNA that are detected overall with fewer than 1 copy per cell may appear abundant in certain types of cells or even in specific nuclear compartments, adding yet another layer of complexity.1

Given their sophisticated nature, lncRNA harbor the ability to be tissue-specific, cell-specific or even compartment-specific. As Adriaens et al7 clearly describe in their article, lncRNA may be best considered to be fine-tuners rather than crucial players. Hence, it is not surprising to find a direct implication of lncRNA in processes such as development or disease. Specifically, in cancer, increasing evidence has strengthened the notion that lncRNA exert cooperative functions to tumor suppression or tumorigenesis. For example, emerging databases, such as Lnc2Cancer (http://www.bio-bigdata.com/lnc2cancer), provide an extensive compilation of lncRNA in relation to different types of cancer and vice versa. Thus, this article aims to outline the implication of lncRNA in the landscape of cancer according to their influence in the gain or loss of oncogenic signatures.

2 | THE LONG NON-CODING RNA CODE IN CANCER

The accumulation of genetic and epigenetic alterations results in an extreme form of somatic mosaicism that may lead to cancer.8 The history of cancer has been ever-evolving, and the fact remains that cancer is a complex disease that certainly demands a complex understanding. Heretofore, the majority of causative evidence for cancer occurrence and progression has been associated with protein-coding regions. Nonetheless, ultraconserved non-coding sequences are commonly found to be deregulated in cancer.9 For instance, single nucleotide polymorphisms (SNP) are among the high-risk alterations associated with cancer occurrence; interestingly, 85% of SNP are annotated in non-coding regions and linked to disease development.9 These abnormalities have an impact on lncRNA, which display altered expression and disrupted functions with subsequent deregulation of their targets.

3 | TUMOR SUPPRESSORS

Most likely, the most notorious gene in cancer research is the tumor suppressor p53 (p53). It works as a transcription factor and activates the expression of multiple genes related to cell cycle arrest and apoptosis. Cellular stress or oncogenic signaling can trigger the activation of p53 through multiple post-translational modifications, and its consequent accumulation in the nucleus substantially increases its detection; however, at normal conditions, its levels are barely detectable.11,12 Several lncRNA are included among the network of p53-transcriptionally activated genes (Table 1).

The lncRNA activator of enhancer domains (LED) has been shown to be involved in a win-win relation with p53. While LED is transcriptionally induced by the same p53, it contributes to the regulation of p53 enhancer-derived transcripts (Figure 1A). Genome-wide characterization showed downregulated expression levels of LED in breast cancer cells, colorectal cancer and androgen-insensitive prostate cancers.13,14 Maternally expressed gene 3 (MEG3) is an imprinted maternal gene that does not currently have a defined function. It interacts with the p53 DNA binding domain, stimulating p53-mediated transactivation (Figure 1B).15 In carcinoma tumors, MEG is conversely related to tumor size and lymphatic metastasis, indicating its strong role as a tumor suppressor and as a potential therapeutic candidate.16 Likewise, downregulated MEG3 has been associated with autophagy and increased cell proliferation in bladder cancer.17 CpG methylation assays pinpointed that MEG3 hypermethylation impacts overall survival in patients with acute myeloid leukemia (AML).18 Another p53-regulated lncRNA is the co-activator of p21 expression, lincRNA-p21. lincRNA-p21 regulates p21 in cis (Figure 1C). Its depletion influences the chromatin status of a few Polycomb target genes that alter the G1/S checkpoint and accelerate cell proliferation.19 In contrast, overactivation of lincRNA-p21 impairs cell proliferation and cell cycle progression in diffuse large B cell lymphoma (DLBCL) cell lines. Consistently high expression levels in DLBCL patients correlate with progression-free and overall survival, resulting in a new potential prognostic marker.20 Studies in colorectal cancer (CRC) show that lincRNA-p21 enhances sensitivity to radiation by targeting the Wnt/B-catenin pathway and promoting apoptosis. In addition, its low expression levels have been correlated with CRC progression.21,22 Not far from the lincRNA-p21 genomic region at approximately 10 kb downstream (3’), we encounter DINO. Its transcription requires p53 to utilize the distinct p53-response elements (p53REs) hosted in the promoter region of CDKN1A. Thereby, DINO is divergently transcribed from CDKN1A, which typically encodes the p21 protein. It participates in optimal activation of the p53 DNA-damage response (DDR) by physically interacting with the C-terminal of p53 (Figure 1D). Consistently, DINO decay impaired the activation of multiple genes of the DDR. Furthermore, preliminary data from colon cancer cell lines showed low expression of DINO at basal conditions and observed differences in expression to drug response.23,24

3.1 | The ambiguity of being a tumor suppressor

One more example of divergent transcription by p53 is the newly found lncRNA GUARDIN. GUARDIN is transcribed from the promoter region of the p53 target gene mir-R-34a, and it is activated upon DDR, promoting cell survival and controlling genome stability. Its depletion results in telomere fusion, inducing senescence and apoptosis. In addition, GUARDIN acts as a scaffold and integrates a ribonucleoprotein (RNP) complex together with the tumor suppressor breast cancer 1 (BRCA1) and its BRCA-associated ring domain (BRCAD1). The overexpression of wild-type p53 and oncogenic mutant HRAS112 increase the levels of GUARDIN in CRC, lung
adenocarcinoma and osteosarcoma cell lines. Moreover, whereas GUARDIN expression is visibly diminished in p53-mutant tumors of CRC, its depletion may induce senescence, apoptosis and abrogate xenograft growth formation.25 Collectively, GUARDIN may be considered to be a good target in p53-mutant tumors; however, further studies are required regarding the ambiguous phenotype that it may present in distinct types of tumors.

The activation of p53 stimulates the formation of paraspeckles, a class of sub-nuclear RNP bodies that participate in transcription and RNA processing. The formation and maintenance of these nuclear complexes depends on their interaction with nuclear enriched abundant transcript 1 (NEAT1).26,27 NEAT1 is a direct target gene of p53 that induces the formation of paraspeckles upon stress. Interestingly, paraspeckles are present in the early stages of cancer. Studies on NEAT1-paraspeckle complexes and tumor formation showed that Neat1 KO mice did not develop chemically-induced skin cancer.28 Likewise, higher expression correlated with unfavorable prognosis in CRC patients.29 However, intriguingly, depletion of NEAT1 inhibited cell growth in breast cancer cells.30 Furthermore, loss of Neat1 in KrasG12D murine models promoted pancreatic precursor lesions and enhanced fibroblast malignant transformation.31 Therefore, the biological relevance of NEAT1 in tumorigenesis should be clarified before it can be considered to be a therapeutic target.

The PTENP1 locus is selectively deleted in colon cancer and melanoma tissues, and its restoration results in the growth inhibition of prostate cancer cells.32,33 Transfection of PTENP1-expressing Sleeping Beauty-based hybrid baculovirus (SB-BV) vectors into mice bearing hepatocellular carcinoma (HCC) tumors mitigates tumor growth and intratumoral cell proliferation by suppressing the oncogenic PI3K-AKT pathway. PTENP1 is a pseudogene of the tumor suppressor PTEN, which functions as a decoy for PTEN-targeting oncomirs miR-17, miR-19b and miR-20a.34,35 Nonetheless, similar to NEAT1, a recent report uncovered a divergence in the activity of PTENP1 linked to the breast cancer phenotype. Whereas overexpression of PTENP1 in estrogen receptor (ER)-negative breast cancers shows its tumor suppressor activity, inhibiting cell growth and enhancing PTEN expression, in ER-positive breast cancers, PTEN expression is decreased, and cell growth is potentiated. Furthermore, in a cohort of 318 patient samples, the presence of PTENP1 was not revealed to have a prognostic impact on human breast cancer.36,37

### Table 1: Tumor suppression-associated lncRNA

| LncRNA | Cancer type | Function | Aberrant phenotype |
|--------|-------------|----------|--------------------|
| LED13,14 | Breast cancer | G1 checkpoint arrest | Enhanced cell proliferation |
| | CRC | Activation of p53-RER and p53-FER | |
| | Androgen-insensitive prostate cancer | | |
| MEG15,18 | Cervical cancer | Induces p53-mediated transactivation | Increased cell proliferation |
| | Bladder cancer | | Autophagy |
| | AML | | |
| Linc-p2119-22 | DLBCL | Regulation in cis of p-21 | Altered G1/S checkpoint |
| | CRC | | Accelerated cell proliferation |
| DINO23,24 | CRC | Transcription of p53 | Drug-resistance |
| | | Activation of p53-induced genes | Impaired DNA-damage response |
| GUARDIN25 | Lung adenocarcinoma | DNA-damage response | Promotion of cell survival and proliferation |
| | Osteosarcoma | Integrates RNP complex | |
| | Breast cancer | BRCA1-BRCAD1 | |
| NEAT126-31 | CRC | Nuclear paraspeckles assembly | Cell growth |
| | Breast cancer | Transcription and RNA processing | Enhanced malignancy |
| | PanIN lesions | | |
| PTENP132-37 | Colon cancer | Decoy of PTEN-targeting oncomirs | Tumor growth |
| | Melanoma | | Activation of PI3K/AKT pathway |
| | Prostate cancer | | |
| | HCC | | |
| | Breast cancer | | |

4 | TUMOR DRIVERS

The metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), also called NEAT2, is an abundant and highly conserved lncRNA across vertebrates. It was first described as a prognostic marker for lung adenocarcinoma.38,39 MALAT1 is recruited to nuclear speckles, which are dynamic compartments destined to processes of mRNA alternative splicing.40,41 Importantly, Malat1 knockout mice develop normally and have a normal life span, showing that MALAT1 is dispensable for
development and normal tissue homeostasis. Depletion of MALAT1 in breast cancer ER-positive luminal cells showed a reduction in cell proliferation, demonstrating its involvement in tumor progression. The chromatin-associated HuR/MALAT1 functional complex controls CD133 gene expression during the dedifferentiation process of breast cancer cells, both in vitro and in vivo. In the most representative form of ovarian cancer, epithelial ovarian cancer (EOC), MALAT1 induces an epithelial-to-mesenchymal transition (EMT) switch via the PI3K/AKT pathway. In CRC tumor tissues, MALAT1 expression has been reported to be a potential predictor of tumor metastasis and prognosis. Similarly, its implication has been reported in studies of glioma, HCC and prostate cancer, among others. Overall, these findings suggest the possibility that the inhibition of MALAT1 might impair cancer-cell growth, metastasis, or both with minimal side effects, making it a promising candidate of drug-targeted therapeutics (Table 2).

Another metastasis-associated IncRNA is the HOX antisense intergenic RNA HOTAIR. Genome-wide analysis from CRC patient specimens supported that HOTAIR is involved in tumor promotion and that its decay enhances radio-sensitivity. In breast cancer, it works as a predictive marker for metastatic progression and overall survival in early-stage surgically resected tumors. Of note, emerging studies on the susceptibility of breast cancer have indicated the
genetic polymorphisms of HOTAIR.\textsuperscript{54,55} HOTAIR acts as a scaffold in a chromatin-repressive mechanism. One of the chromatin-modifying complexes is the polycomb repressive complex 2 (PRC2), which catalyzes the repressive histone mark H3K27me3. Intriguingly, in breast cancer, HOTAIR repression is PRC2-independent and influences the expression of a limited number of target genes, suggesting a distinct function for PCR2-RNA binding other than chromatin targeting.\textsuperscript{56}

An interesting new report suggests that MALAT1 and HOTAIR are ER transcriptional targets and mediators in the ER-dependent or ER-independent transcriptional response in prostate cancer. MALAT1 and HOTAIR, which have been shown to be associated with ER\textsubscript{α}/ER\textsubscript{β} at the chromatin level, display different mechanisms to abrogate the ER response, suggesting a new type of hormone action.\textsuperscript{57} The IncRNA NORAD is regulated in the DDR and exerts a key role on chromosomal instability.\textsuperscript{58,59} Whereas NORAD\textsuperscript{-/-} cells develop genomic instability and aneuploidy, the overactivation of NORAD is significantly found in tissues of CRC, esophageal squamous cell carcinoma (ESCC) and bladder cancer, contributing to tumor progression.\textsuperscript{59-62} In an attempt to determine whether a low-copy-number gain of the genes accompanying MYC in the 8q24.21 region generates neoplasia, chromosome engineering was used in mice. These results revealed that high levels of Myc protein are dependent upon IncRNA PVT1 to promote tumor development and that Myc alone is insufficient otherwise.\textsuperscript{63} Concomitantly, PVT1-null CRC cell lines

### Table 2: Tumor promotion-associated LncRNA

| LncRNA | Cancer type                      | Function                                      | Aberrant phenotype                     |
|--------|----------------------------------|-----------------------------------------------|----------------------------------------|
| MALAT\textsuperscript{1}\textsuperscript{38-50} | Lung adenocarcinoma, Breast cancer, Ovarian cancer, CRC, Glioma, HCC, Prostate cancer | Nuclear speckles scaffold mRNA splicing | Tumor progression, Metastatic-phenotype induction |
| HOTAIR\textsuperscript{51-56} | CRC, Breast cancer, Prostate cancer | Repressive chromatin marks, Recruitment of PRC | Tumor promotion, Decreased radio-sensitivity |
| NORAD\textsuperscript{58-62} | CRC, ESCC, Bladder cancer | Negative regulator of RNA-binding proteins PUMILLO | Chromosomal instability |
| PVT1\textsuperscript{63-66} | CRC, Bladder cancer, Cervical cancer | Epigenetic arrest of G1 checkpoint | Expression of c-MYC, Uncontrolled cell proliferation |

CRC, colorectal cancer; LncRNA, long non-coding RNA.

**Figure 2** Long non-coding RNA (LncRNA) involved in tumor plasticity. Aberrantly expressed LncRNA may have an important impact in the EMT-MET processes by interacting with diverse signaling cascades.
failed to generate xenograft tumors. Consistent data highlight the relevance of PVT1 in MYC-driven cancers, such as CRC, bladder cancer and cervical cancer.64–66

5 | LONG NON-CODING RNA AND TUMOR PLASTICITY

The tumor microenvironment is represented by the presence of non-tumoral cells and modified extracellular matrix. In this scenario, tumor cells meet stromal and immune cells, leveraging interactions and contributing to tumor progression. As a result of intercellular communication, subpopulations of cancer cells acquire new properties of plasticity, stem-like features and immune suppression and are prone to becoming resistant to therapy. Reprogramming into new phenotypes requires EMT. EMT may be induced through different biological stimuli, and it is regulated by transcriptional factors.67,68 Better pharmacological targeting of cancer-associated lncRNA is a must for understanding their participation at distinct cancer levels.

Tumor stroma cells from breast cancer were found to preferentially express MEG3.69 Genome-wide mapping of MEG3 in ovarian cancer shows that it is significantly associated with EMT-linked canonical pathways. Genome-wide analysis highlighted the epigenetic regulation of EMT in lung adenocarcinoma.70,71 When lincRNA-p21 is overexpressed in HCC, N-cadherin and snail expression is decreased, inhibiting the EMT.72 Consistently, its depletion in gastric cancer promotes EMT phenotypic changes in cells, and these changes are also seen at the transcriptome level.73 In nasopharyngeal carcinoma (NPC), NEAT1 regulates EMT via the miR-204/ZEB1 axis, and breast cancer cells show decreased β-catenin and N-cadherin and increased E-cadherin after NEAT1 suppression.74,75 Furthermore, NEAT1 can epigenetically suppress E-cadherin expression through the association of G9a-DNMT1-Snail complex.76 MALAT1 intervenes in the endothelial-to-mesenchymal transition (EndMT) induced by TGFβ1, a key mediator between stromal and cancer cells. Its silencing hinders EMT via PI3K-AKT in ovarian cancer and can result in different phenotypes depending on breast cancer subtypes.44,45 Of note, triple negative breast cancer generally displays lower levels of MALAT1 per se than luminal phenotypes. Indeed, as we have noted, tissue/cell-specificity has major significance. HOTAIR acts as a scaffold by recruiting EZH2 to Snail, forming a repressive complex that suppresses E-cadherin and promotes mesenchymal phenotypes in non-tumorigenic hepatocytes. Consistently, in HCC, EZH2/ HOTAIR/Snail are upregulated and correlate with tumor progression and aggressiveness.77 In breast cancer, cancer-associated fibroblasts (CAF) transcriptionally activate HOTAIR through the direct binding of SMAD2/3/4 to the HOTAIR promoter region. Then, HOTAIR epigenetically represses CDK5RAP1, stimulating CDK5 signaling and inducing EMT.78 PVT1 acts as competing endogenous RNA (ceRNA) for miR152, activating Hedgehog signaling and promoting EMT in hepatic stellate cells and thereby contributing to liver fibrosis.79 Likewise, the overexpression of PVT1 resulted in an increase of Snail and ZEB1 expression in pancreatic cancer (Figure 2).80

6 | CONCLUDING REMARKS

Collectively, these studies highlight the importance of IncRNA in the cancer landscape. IncRNA are capable of tuning gene expression and impacting cellular signaling cascades. Occasionally, this impact can be easily seen at the phenotypic level; however, in other cases, it may result in more subtle phenotypes that can solely be detected after comprehensive analysis. The latter must be considered carefully; based on their translational relevance, the pharmacological targeting of IncRNA that display minor phenotypes upon depletion may represent an opportunity for clinical application.

CONFLICT OF INTEREST

The authors have no conflicts of interest to declare.

ORCID

Anna Sanchez Calle https://orcid.org/0000-0002-1127-5822
Yumi Kawamura https://orcid.org/0000-0001-8386-4645
Takahiro Ochiya https://orcid.org/0000-0002-0776-9918

REFERENCES

1. Djebali S, Davis CA, Merkel A, et al. Landscape of transcription in human cells. Nature. 2012;489:101-108.
2. The FANTOM Consortium and the RIKEN PMI and CLST (DGT). A promoter-level mammalian expression atlas. Nature. 2014;507:462-470.
3. de Hoon M, Shin JW, Carninci P. Paradigm shifts in genomics through the FANTOM projects. Mamm Genome. 2015;26:391-402.
4. Iyer MK, Niknafs YS, Malik R, et al. The landscape of long noncoding RNAs in the human transcriptome. Nat Genet. 2015;47:199-208.
5. Geisler S, Coller J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol. 2013;14:699-712.
6. Ulltsey I, Bartel DP. lncRNAs: genomics, evolution, and mechanisms. Cell. 2013;154:26-46.
7. Adriaens C, Marine JC. NEAT1-containing paraspeckles: central hubs in stress response and tumor formation. Cell Cycle. 2017;16:137-138.
8. Fernández LC, Torres M, Real FX. Somatic mosaicism: on the road to cancer. Nat Rev Cancer. 2016;16:43-55.
9. Calin GA, Liu CG, Ferracin M, et al. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell. 2007;12:215-229.
10. Freedman ML, Monteiro AN, Gayther SA, et al. Principles for the post-GWAS functional characterization of cancer risk loci. Nat Genet. 2011;43:513-518.
11. Real FX. p53: it has it all, but will it make it to the clinic as a marker in bladder cancer? J Clin Oncol. 2007;25:5341-5344.
12. Ozaki T, Nakagawa A. Role of p53 in cell death and human cancers. Cancers (Basel). 2011;3:994-1013.
13. Léveillé N, Melo CA, Rooijers K, et al. Genome-wide profiling of p53-regulated enhancer RNAs uncovers a subset of enhancers controlled by a lncRNA. Nat Commun. 2015;6:6520.
14. Zhao H, Kim Y, Wang P, et al. Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines. Prostate. 2005;63:187-197.
15. Zhu J, Liu S, Ye F, et al. Long noncoding RNA MEG3 interacts with p53 protein and regulates partial p53 target genes in hepatoma cells. PLoS ONE. 2015;10:e0139770.
16. Zhang J, Yao T, Wang Y, et al. Long noncoding RNA MEG3 is downregulated in cervical cancer and affects cell proliferation and apoptosis by regulating miR-21. Cancer Biol Ther. 2017;16:104-113.
17. Ying L, Huang Y, Chen H, et al. Downregulated MEG3 activates autophagy and increases cell proliferation in bladder cancer. Mol Biol Syst. 2013;9:407-411.
18. Benetatos L, Hatzimichael E, Dasoula A, et al. CpG methylation analysis of the MEGS and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes. Leuk Res. 2010;34:148-152.
19. Dimitrova N, Zamudio JR, Jong RM, et al. LncRNA-p21 activates p21 in cis to promote Polycomb target gene expression and to enforce the G1/S checkpoint. Mol Cell. 2014;54:777-790.
20. Peng W, Wu J, Feng J. LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy. Clin Exp Med. 2017;17:1-8.
21. Wang G, Li Z, Zhao Q, et al. LincRNA-p21 enhances the sensitivity of radiotherapy for human colorectal cancer by targeting the Wnt/β-catenin signaling pathway. Oncol Rep. 2014;31:1839.
22. Zhai H, Fesler A, Schee K, Fodstad O, Flatmark K, Ju J. Clinical significance of long intergenic noncoding RNA-p21 in colorectal cancer. J Clin Oncol. 2013;12:261-266.
23. Schmitt AM, Garcia JT, Hung T, et al. An inducible long noncoding RNA amplifies DNA damage signaling. Nat Genet. 2016;48:1370-1376.
24. Huarte M. p53 partners with RNA in the DNA damage response. Genes Dev. 2017;31:1095-1108.
25. Adriaens C, Standaert L, Barra J, et al. p53 induces formation of NEAT1 IncRNA-containing paraspeckles that modulate replication stress response and chemosensitivity. Nat Med. 2016;22:861-868.
26. Ke H, Zhao L, Feng X, et al. NEAT1 is required for survival of breast cancer cells. Oncogene. 2017;36:981-994.
27. Li Y, Li Y, Chen W, et al. NEAT1 is a p53-inducible lincRNA essential for transformation suppression. Genes Dev. 2017;31:1095-1108.
28. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfo PP. A coding-independent function of gene and pseudogene mRNAs regulates tumor biology. Nature. 2010;465:1033-1038.
29. Chen M. Smoke and miRors: pseudogenes tricks miRNAs. Pigment Cell Melanoma Res. 2010;23:583-584.
30. Chen CL, Tseng YW, Wu JC, et al. Suppression of hepatocellular carcinoma by baculovirus-mediated expression of long non-coding RNA PTENP1 and MicroRNA regulation. Biomaterials. 2015;44:71-81.
31. Mao T, Liang O. ULK1 can suppress or promote tumor growth under different conditions. Autophagy. 2017;12:245-257.
32. Yndestad S, Austreid E, SkafteNesmo KO, et al. Divergent activity of the pseudogene PTENP1 in ER-positive and negative breast cancer. Mol Cancer Res. 2018;16:78-89.
33. Yndestad S, Austreid E, Knappskog S, et al. High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function. Breast Cancer Res Treat. 2017;163:177-190.
34. Arun G, Diermeier S, Akerman M, et al. Differentiation of mammary tumors and reduction in metastasis upon Malat1 IncRNA loss. Genes Dev. 2016;30:34-51.
35. Gutsch T, Hammerle M, Eissmann M, et al. The noncoding RNA MALAT1 is critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013;73:1180-1189.
36. Miyagawa R, Tano K, Mizuno R, et al. Identification of cis- and trans-acting factors involved in the localization of MALAT-1 noncoding RNA to nuclear speckles. RNA. 2012;18:738-751.
37. Tripathi V, Ellis JD, Shen Z, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 2010;39:925-938.
38. Zhang B, Arun G, Mao YS, et al. The IncRNA Malat 1 is dispensable for mouse development but its transcription plays a cis-regulatory role in the adult. Cell Rep. 2012;2:111-123.
39. Jadaliha M, Zong X, Malakar P, et al. Functional and prognostic significance of long non-coding RNA MALAT1 as a metastasis driver in ER negative lymph node negative breast cancer. Oncotarget. 2016;7:40418-40436.
40. Latorre E, Carelli S, Raimondi I, et al. The ribonucleic complex H3R-MALAT1 represses CD133 expression and suppresses epithelial-mesenchymal transition in breast cancer. Cancer Res. 2016;76:2626-2636.
41. Jin Y, Feng SJ, Qiu S, Shao N, Zheng JH. LncRNA MALAT1 promotes proliferation and metastasis in epithelial ovarian cancer via the PI3K-AKT pathway. Eur Rev Med Pharmacol Sci. 2017;21:3176-3184.
42. Ji Q, Zhang L, Liu X, et al. Long non-coding RNA MALAT1 promotes tumor growth and metastasis in colorectal cancer through binding to sFPO and releasing oncoscne PTBP2 from sFPQ/PTBP2 complex. Br J Cancer. 2014;111:736-748.
43. Zheng HT, Shi DB, Wang YW, et al. High expression of IncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer. Int J Clin Exp Pathol. 2014;7:3174-3181.
44. Ma J, Wang P, Yao Y, et al. Knockdown of long non-coding RNA MALAT1 increases the blood-tumor barrier permeability by up-regulating miR-140. Biochim Biophys Acta. 2016;1859:324-338.
45. Lin R, Maeda S, Liu C, Karim M, Edgington TS. A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene. 2007;26:851-858.
46. Wang D, Ding L, Wang L, et al. LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer. Oncotarget. 2016;5:41045-41055.
47. Xue Y, Ma G, Gu D, et al. Genome-wide analysis of long noncoding RNA signature in human colorectal cancer. Cancer Res. 2015;55:227-234.
48. Yang XD, Xu HT, Xu XH, et al. Knockdown of long non-coding RNA HOTAIR inhibits proliferation and invasiveness and improves radiosensitivity in colorectal cancer. Oncol Rep. 2016;35:479-487.
49. Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464:1071-1076.
50. Lin Y, Guo W, Li N, Fu F, Lin S, Wang C. Polyphosphominds of long non-coding RNA HOTAIR with breast cancer susceptibility and clinical outcomes for a southeast Chinese Han population. Oncotarget. 2017;9:3677-3689.
51. Hassanzarei S, Hashemi M, Sattarifard H, Hashemi SM, Bahari G, Ghavami S. Genetic polymorphisms of HOTAIR gene are associated with the risk of breast cancer in a sample of southeast Iranian population. Cancer Biol Ther. 2017;18:245-257.
52. Portoso M, Ragazzini R, Bencić Z, et al. PRC2 is dispensable for mouse development but its transcription plays a cis-regulatory role in the adult. Cell Rep. 2012;2:111-123.
53. Ventura A. NORAD: defender of the Genome. Trends Genet. 2016;32:390-392.
59. Lee S, Kopp F, Chang TC, et al. Noncoding RNA NORAD regulates genomic stability by sequestering PUMILLO proteins. Cell. 2016;164:69-80.

60. Zhang J, Li XY, Hu P, Ding YS. LncRNA NORAD contributes to colorectal cancer progression by inhibition of miR-202-5p. Oncol Res. 2018. https://doi.org/10.3727/096504018x15190844870055.

61. Wu X, Lin ZF, Li Z, et al. NORAD expression is associated with adverse prognosis in esophageal squamous cell carcinoma. Oncol Res Treat. 2017;40:370-374.

62. Li Q, Li C, Chen J, et al. High expression of long noncoding RNA NORAD indicates a poor prognosis and promotes clinical progression and metastasis in bladder cancer. Urol Oncol. 2018;36:310.e15-310.e22.

63. Tseng YY, Moriarity BS, Gong W, et al. PVT1 dependence in cancer with MYC copy-number increase. Nature. 2014;512:82-86.

64. Takahashi Y, Sawada G, Kurashige J, et al. Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers. Br J Cancer. 2014;110:164-171.

65. Zhuang C, Li J, Liu Y, et al. Tetracycline-inducible shRNA targeting long non-coding RNA PVT1 inhibits cell growth and induces apoptosis in bladder cancer cells. Oncotarget. 2015;6:41194-41203.

66. Zhang Z, Zhang G, Liu J. Long noncoding RNA PVT1 promotes cervical cancer progression through epigenetically silencing miR-200b. APMIS. 2016;124:649-658.

67. Meseure D, Drak Alsibai K, Nicolas A. Pivotal role of pervasive neoplastic and stromal cells reprogramming in circulating tumor cells dissemination and metastatic colonization. Cancer Microenviron. 2014;7:95-115.

68. Drak Alsibai K, Meseure D. Tumor microenvironment and noncoding RNAs as co-drivers of epithelial-mesenchymal transition and cancer metastasis. Dev Dyn. 2018;247:405-431.

69. Zhang Z, Weaver DL, Olsen D, et al. Long non-coding RNA chromogenic in situ hybridization signal pattern correlation with breast tumor pathology. J Clin Pathol. 2016;69:76-81.

70. Mitra R, Chen X, Greenawalt EJ, et al. Decoding critical long non-coding RNA in ovarian cancer epithelial-to-mesenchymal transition. Nat Commun. 2017;8:1604.

71. Terasima M, Tange S, Ishimura A, Suzuki T. MEG3 long noncoding RNA contributes to the epigenetic regulation of epithelial-mesenchymal transition in lung cancer cell lines. J Biol Chem. 2017;292:82-99.

72. Jia M, Jiang L, Wang YD, Huang JZ, Yu M, Xue HZ. lincRNA-p21 inhibits invasion and metastasis of hepatocellular carcinoma through Notch signaling-induced epithelial-mesenchymal transition. Hepatol Res. 2016;46:1137-1144.

73. Chen Y, Wei G, Xia H, Yu H, Tang Q, Bi F. Down regulation of lncRNA-p21 contributes to gastric cancer development through Hippo-independent activation of YAP. Oncotarget. 2017;8:63813-63824.

74. Lu Y, Li T, Wei G, et al. The long non-coding RNA NEAT1 regulates epithelial to mesenchymal transition and radioresistance in through miR-204/2EB1 axis in nasopharyngeal carcinoma. Tumor Biol. 2016;37:11733-11741.

75. Zhang M, Wu WB, Wang ZW, Wang XH. LncRNA NEAT1 is closely related with progression of breast cancer via promoting proliferation and EMT. Eur Rev Med Pharmacol Sci. 2017;21:1020-1026.

76. Li Y, Cheng C. Long noncoding RNA NEAT1 promotes the metastasis of osteosarcoma via interaction with the G9a-DNMT1-Snail complex. Am J Cancer Res. 2018;8:81-90.

77. Battistelli C, Cicchini C, Santangelo L, et al. The Snail repressor recruits EZH2 to specific genomic sites through the enrollment of the lncRNA HOTAIR in epithelial-to-mesenchymal transition. Oncogene. 2017;36:942-955.

78. Ren Y, Jia HH, Xu YQ, et al. Paracrine and epigenetic control of CAF-induced metastasis: the role of HOTAIR stimulated by TGF-ß1 secretion. Mol Cancer. 2018;17:5.

79. Zheng J, Yu F, Dong P, et al. Long non-coding RNA PVT1 activates hepatic stellate cells through competitively binding microRNA-152. Oncotarget. 2016;7:62886-62897.

80. Wu BQ, Jiang Y, Zhu F, et al. Long noncoding RNA PVT1 promotes EMT and cell proliferation and migration through downregulating p21 in pancreatic cancer cells. Technol Cancer Res Treat. 2017;16:819-827.

How to cite this article: Sanchez Calle A, Kawamura Y, Yamamoto Y, Takeshita F, Ochiya T. Emerging roles of long non-coding RNA in cancer. Cancer Sci. 2018;109:2093–2100. https://doi.org/10.1111/cas.13642